Shots:
- Part A of P-lll study involves assessing of Dupixent (qw, 300mg) vs PBO in 81 patients aged≥ 12 yrs. with EoE. The study resulted in meeting its co-primary and all key 2EPs, presented at the virtual ACG 2020 and UEG Week 2020
- Results: Patients reported significant improvement on DSQ as 4 wks. and continued to improve through 24 wks; reduced EEC (<15) eos/hpf (64% vs 8%) @24wks. Peak EEC (71% vs 3%). ET changes associated with the disease reduced (0.761 and 0.753 vs 0.001 and 0.012) reduction @24wks.; gene expression patterns associated with type 2 inflammation and EoE were reduced (1.97-fold & 2.66-fold vs 0.32-fold & 0.16-fold); SAEs (86% vs 82%)
- Dupixent is mAb inhibiting the signaling of the IL-4 and IL-13 proteins and has received the US FDA’s BT designation for the treatment of patients ≥12yrs. with EoE
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Chemistry World
The post Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE) first appeared on PharmaShots.
